Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hu, Theodore ^a   Chung, Young Min ^a   Guan, Michelle ^a   Ma, Michael ^a   Ma, Jessica ^a   Berek, Jonathan S ^a   Hu, Mickey C T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; IRINOTECAN; METFORMIN;

ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; TUMOR CELL LINE; TUMOR VOLUME;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONES; METFORMIN; MICE, NUDE; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904802910     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05810     Document Type: Article

References (57)

1. Bray, F. et al. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132, 1133-1145 (2013
2. Ricci, M. S. & Zong, W. X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11, 342-357 (2006
3. Abdullah, L. N. & Chow, E. K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2, 3 (2013
4. Ghiaur, G.,Gerber, J. & Jones, R. J. Concise review: Cancer stem cells and minimal residual disease. Stem Cells 30, 89-93 (2012
5. Pham, P. V. et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J. Transl. Med. 9, 209 (2011
6. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012
7. McGuire, W. P. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996
8. Ozols, R. F. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 21, 3194-3200 (2003 (Pubitemid 46606249)
9. Goodarzi, M. O. & Bryer-Ash, M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes. Metab. 7, 654-665 (2005 (Pubitemid 41601070)
10. Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167-1174 (2001 (Pubitemid 32995375)
11. Evans, J. M. et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 (2005 (Pubitemid 40813563)
12. Bowker, S. L. et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258 (2006 (Pubitemid 44106500)
13. Anisimov, V. N. et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol. 40, 685-693 (2005 (Pubitemid 41265819)
14. Schneider, M. B. et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120, 1263-1270 (2001 (Pubitemid 32246678)
15. Guastamacchia, E. et al. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4, 59-66 (2004 (Pubitemid 38854882)
16. Zakikhani, M. et al.Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66, 10269-10273 (2006 (Pubitemid 44799743)
17. Kefas, B. A. et al. Metformin-induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. Biochem. Pharmacol. 68, 409-416 (2004 (Pubitemid 38887423)
18. Alvarez, B. et al. Forkhead transcription factors contribute to execution of the mitotic programme in mammals. Nature 413, 744-747 (2001 (Pubitemid 33009953)
19. Nemoto, S., Fergusson, M. M. & Finkel, T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306, 2105-2108 (2004 (Pubitemid 40007664)
20. Tran, H. et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530-534 (2002 (Pubitemid 34408672)
21. Tsai, W. B. et al. Functional interaction between FOXO3 andATMregulatesDNA damage response. Nat. Cell Biol. 10, 460-467 (2008
22. Furukawa-Hibi, Y. et al. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid. Redox Signal 7, 752-760 (2005 (Pubitemid 40563215)
23. Greer, E. L. & Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005 (Pubitemid 41637981)
24. Willcox, B. J. et al. FOXO3A genotype is strongly associated with human longevity. Proc. Natl Acad. Sci. USA 105, 13987-13992 (2008
25. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999 (Pubitemid 29165088)
26. Sunters, A. et al. FOXO3 transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J. Biol. Chem. 278, 49795-49805 (2003 (Pubitemid 37548813)
27. Yang, J. Y. et al. Induction of FOXO3a and Bim expression in response to ionizing radiation. Int. J. Oncol. 29, 643-648 (2006
28. Hu, M. C. et al. IkB kinase promotes tumourigenesis through inhibition of Forkhead FOXO3. Cell 117, 225-237 (2004 (Pubitemid 38496242)
29. Seoane, J. et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (2004 (Pubitemid 38496241)
30. Habashy, H. O. et al. FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res. Treat. 129, 11-21 (2011
31. Jiang, Y. et al. Foxo3a expression is a prognostic marker in breast cancer. PLoS One 8, e70746 (2013
32. Paik, J. H. et al. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell 128, 309-323 (2007
33. Miyamoto, K. et al. FOXO3 is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1, 101-112 (2007 (Pubitemid 46865800)
34. Fei, M. et al. Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest. 27, 52-59 (2009
35. Zamboni, W. C. et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin. Cancer Res. 4, 743-753 (1998 (Pubitemid 28193575)
36. Benson, A. B. et al.Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J. Natl. Compr. Canc. Netw. 11, 141-152 (2013
37. Schmoll, H. J. et al. ESMOConsensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 23, 2479-2516 (2012
38. Hertzberg, R. P. et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem. 32, 715-720 (1989 (Pubitemid 19075732)
39. Kawato, Y. et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 51, 4187-4191 (1991
40. Hein, J. et al. Simian virus 40 large T antigen disrupts genome integrity and activates a DNA damage response via Bub1 binding. J. Virol. 83, 117-127 (2009
41. Rodier, F. et al. DNA-SCARS: distinct nuclear structures that sustain damageinduced senescence growth arrest and inflammatory cytokine secretion. J. Cell Sci. 124, 68-81 (2011
42. Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320 (2008
43. Louderbough, J. M. & Schroeder, J. A. Understanding the dual nature of CD44 in breast cancer progression. Mol. Cancer Res. 9, 1573-1586 (2011
44. Bakkenist, C. J. & Kastan, M. B. Initiating cellular stress responses. Cell 118, 9-17 (2004 (Pubitemid 38902810)
45. Chung, Y. M. et al. FOXO3 signalling links ATM to the p53 apoptotic pathway following DNA damage. Nat. Commun. 3, 1000 (2012
46. Greer, E. L. et al. The energy sensor AMP activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. 282, 30107-30119 (2007 (Pubitemid 350035296)
47. Banko, M. R. et al. Chemical genetic screen for AMPKa2 substrates uncovers a network of proteins involved in mitosis. Mol. Cell 44, 878-892 (2011
48. Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J. F. & Bost, F. Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol. Cancer Ther. 9, 1092-1099 (2010
49. Garofalo, C. et al. Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS One 8, e83832 (2013
50. Fendt, S. M. et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73, 4429-4438 (2013
51. Rattan, R. et al.Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13, 483-491 (2011
52. Maurya, D. K. et al. Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo. J. Environ. Pathol. Toxicol. Oncol. 30, 1-10 (2011
53. Wallin, A. et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol. Rep. 19, 1493-1498 (2008
54. Croker, A. K. et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J. Cell Mol. Med. 13, 2236-2252 (2009
55. Lyssiotis, C. A. et al. Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc. Natl. Acad. Sci. USA 106, 8912-8917 (2009
56. Bast, R. C. Jr. et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337 (1981 (Pubitemid 12235035)
57. Tsai, W. B. et al. Inhibition of FOXO3 tumor suppressor function by bTrCP1 through ubiquitin-mediated degradation in a tumor mouse model. PLoS ONE 5, e11171 (2010).